MS
MTCR

Maven Securities’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Maven Securities’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-19,246
Closed -$197K – 924
2020
Q3 		$197K Buy
+19,246
New +$197K 0.02% 562

Other funds holding MTCR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Maven Securities's MTCR Position: Q4 2020 in Review

Maven Securities sold out of Metacrine, Inc. Common Stock (MTCR) in Q4 2020, closing a stake of 19,246 shares — an estimated $197K sold.

Maven Securities first reported a position in MTCR in Q3 2020 and held it in 1 quarter. The position peaked at $197K in Q3 2020. 42 funds tracked by Wall St. Rank hold MTCR as of Q4 2020.

  • Maven Securities reported no remaining Metacrine, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Maven Securities sold 19,246 Metacrine, Inc. Common Stock shares in Q4 2020, an estimated $197K.
  • Maven Securities first reported a position in Metacrine, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Maven Securities's Metacrine, Inc. Common Stock position peaked at $197K in Q3 2020.
  • 42 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q4 2020.

Based on Maven Securities's 13F filing for Q4 2020, filed 12 Feb 2021.